MX366136B - Derivados de ariletinilo. - Google Patents
Derivados de ariletinilo.Info
- Publication number
- MX366136B MX366136B MX2015003560A MX2015003560A MX366136B MX 366136 B MX366136 B MX 366136B MX 2015003560 A MX2015003560 A MX 2015003560A MX 2015003560 A MX2015003560 A MX 2015003560A MX 366136 B MX366136 B MX 366136B
- Authority
- MX
- Mexico
- Prior art keywords
- fluorophenyl
- formula
- compounds
- derivatives
- sydrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a derivados de etinilo de la fórmula (I) en donde R1 es fenilo, 3-fluorfenilo, 4- fluorfenilo o 2,5-di-fluor-fenilo; o a una sal de adición de ácido farmacéuticamente aceptable, en forma enantioméricamente pura con la configuración absoluta representada en la fórmula (I). Ahora se ha encontrado de modo sorprendente que los compuestos de la fórmula general 1 son moduladores alostéricos del receptor de glutamato metabotrópico del subtipo 5 (mGluR5), que posee propiedades bioquímicas, físico-químicas y farmacodinámicas ventajosas con respecto a los compuestos del arte previo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186265 | 2012-09-27 | ||
| PCT/EP2013/069674 WO2014056710A1 (en) | 2012-09-27 | 2013-09-23 | Arylethynyl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003560A MX2015003560A (es) | 2015-06-22 |
| MX366136B true MX366136B (es) | 2019-06-28 |
Family
ID=47044829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003560A MX366136B (es) | 2012-09-27 | 2013-09-23 | Derivados de ariletinilo. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9221802B2 (es) |
| EP (1) | EP2900659B1 (es) |
| JP (1) | JP6027251B2 (es) |
| KR (1) | KR101737245B1 (es) |
| CN (1) | CN104684911B (es) |
| AR (1) | AR092673A1 (es) |
| AU (1) | AU2013329739B2 (es) |
| BR (1) | BR112015006218A2 (es) |
| CA (1) | CA2885382A1 (es) |
| CL (1) | CL2015000707A1 (es) |
| CR (1) | CR20150139A (es) |
| DK (1) | DK2900659T3 (es) |
| EA (1) | EA025482B1 (es) |
| ES (1) | ES2594031T3 (es) |
| HK (1) | HK1207376A1 (es) |
| HU (1) | HUE029636T2 (es) |
| IL (1) | IL237596A (es) |
| MA (1) | MA37941B1 (es) |
| MX (1) | MX366136B (es) |
| MY (1) | MY171743A (es) |
| NZ (1) | NZ706283A (es) |
| PE (1) | PE20150708A1 (es) |
| PH (1) | PH12015500538A1 (es) |
| PL (1) | PL2900659T3 (es) |
| SG (1) | SG11201502449RA (es) |
| SI (1) | SI2900659T1 (es) |
| TW (1) | TWI476194B (es) |
| UA (1) | UA113779C2 (es) |
| WO (1) | WO2014056710A1 (es) |
| ZA (1) | ZA201501678B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| PE20150733A1 (es) * | 2012-10-18 | 2015-05-17 | Hoffmann La Roche | Derivados de etinilo como moduladores de la actividad del receptor mglur5 |
| CR20170536A (es) * | 2015-06-03 | 2018-02-01 | Hoffmann La Roche | Derivados de etinilo |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP1809620B1 (en) | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| JP5622568B2 (ja) | 2007-06-03 | 2014-11-12 | バンダービルト ユニバーシティ | ベンズアミドｍＧｌｕＲ５の正のアロステリック調節因子ならびにその作製および使用方法 |
| US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
-
2013
- 2013-09-23 MX MX2015003560A patent/MX366136B/es active IP Right Grant
- 2013-09-23 DK DK13766286.2T patent/DK2900659T3/en active
- 2013-09-23 ES ES13766286.2T patent/ES2594031T3/es active Active
- 2013-09-23 SI SI201330373A patent/SI2900659T1/sl unknown
- 2013-09-23 EP EP13766286.2A patent/EP2900659B1/en active Active
- 2013-09-23 MY MYPI2015000777A patent/MY171743A/en unknown
- 2013-09-23 HU HUE13766286A patent/HUE029636T2/en unknown
- 2013-09-23 CA CA2885382A patent/CA2885382A1/en not_active Abandoned
- 2013-09-23 SG SG11201502449RA patent/SG11201502449RA/en unknown
- 2013-09-23 WO PCT/EP2013/069674 patent/WO2014056710A1/en active Application Filing
- 2013-09-23 AU AU2013329739A patent/AU2013329739B2/en not_active Ceased
- 2013-09-23 NZ NZ706283A patent/NZ706283A/en not_active IP Right Cessation
- 2013-09-23 BR BR112015006218A patent/BR112015006218A2/pt not_active IP Right Cessation
- 2013-09-23 EA EA201590557A patent/EA025482B1/ru not_active IP Right Cessation
- 2013-09-23 PL PL13766286T patent/PL2900659T3/pl unknown
- 2013-09-23 PE PE2015000422A patent/PE20150708A1/es active IP Right Grant
- 2013-09-23 JP JP2015533547A patent/JP6027251B2/ja active Active
- 2013-09-23 UA UAA201503791A patent/UA113779C2/uk unknown
- 2013-09-23 CN CN201380050037.9A patent/CN104684911B/zh active Active
- 2013-09-23 KR KR1020157010351A patent/KR101737245B1/ko active IP Right Grant
- 2013-09-25 AR ARP130103433A patent/AR092673A1/es unknown
- 2013-09-26 TW TW102134845A patent/TWI476194B/zh not_active IP Right Cessation
-
2015
- 2015-03-05 IL IL237596A patent/IL237596A/en active IP Right Grant
- 2015-03-11 ZA ZA2015/01678A patent/ZA201501678B/en unknown
- 2015-03-12 PH PH12015500538A patent/PH12015500538A1/en unknown
- 2015-03-16 CR CR20150139A patent/CR20150139A/es unknown
- 2015-03-20 CL CL2015000707A patent/CL2015000707A1/es unknown
- 2015-03-20 MA MA37941A patent/MA37941B1/fr unknown
- 2015-03-26 US US14/669,653 patent/US9221802B2/en active Active
- 2015-08-19 HK HK15108049.7A patent/HK1207376A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| MX2014002442A (es) | Inhibidores de pirrolopirazina cinasa. | |
| NZ601024A (en) | Arylethynyl derivatives | |
| MD4664C9 (ro) | Lactame aril şi heteroaril condensate | |
| PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| MX352928B (es) | Compuestos de piridazina-amida. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA033513B1 (ru) | Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения | |
| IN2014CN04530A (es) | ||
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| IN2014CN04449A (es) | ||
| MX364400B (es) | Compuestos de tetraciclina. | |
| GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| IN2013DN02555A (es) | ||
| PH12015500538A1 (en) | Arylethynyl derivatives | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| PH12014502695A1 (en) | Arylethynyl derivatives | |
| PH12014502747A1 (en) | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide | |
| GEP20146182B (en) | Delta crystalline form of arginine salt of perindopril, process for its preparation, and pharmaceutical com¬po¬- sitions containing it | |
| PH12015500261A1 (en) | Arylethynyl pyrimidines | |
| MX2013005050A (es) | Derivados de indol. | |
| TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TN2013000122A1 (en) | Oxadiazole inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |